Cargando…

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

This study aimed to investigate the role of bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) who had developed acquired resistance to EGFR-TKIs therapy that manifested as malignant pleural effusion (MPE). In total, 86 patients were included. 47 patients received bevacizumab p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Tao, Li, Aiwu, Su, Chunxia, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617537/ https://www.ncbi.nlm.nih.gov/pubmed/28977977 http://dx.doi.org/10.18632/oncotarget.16061

Ejemplares similares

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
por: Yang, Hainan, et al.
Publicado: (2022)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma
por: Jeong, Hyoung-oh, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion
por: Shan, Yi, et al.
Publicado: (2017)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
por: Falk, Markus, et al.
Publicado: (2023)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
por: Verma, Akash, et al.
Publicado: (2016)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance
por: Zhou, Juan, et al.
Publicado: (2023)

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
por: Tao, Hong, et al.
Publicado: (2018)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
por: Jiang, Tao, et al.
Publicado: (2021)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

Identification of biomarkers, pathways, and therapeutic targets for EGFR–TKI resistance in NSCLC
por: Zhu, Leilei, et al.
Publicado: (2023)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
por: Urbanska, Edyta M., et al.
Publicado: (2023)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
por: Zhang, Yongchang, et al.
Publicado: (2021)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Malignant Müllerian Adenocarcinoma Manifesting With Cardiac Tamponade and Pleural Effusion
por: Maaliki, Naji, et al.
Publicado: (2021)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
por: Qi, Nan, et al.
Publicado: (2016)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r43atb0ee8krko436g4k0lfp79